Thomas Brodowicz

10.1k total citations · 1 hit paper
126 papers, 3.4k citations indexed

About

Thomas Brodowicz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Thomas Brodowicz has authored 126 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Oncology, 67 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Thomas Brodowicz's work include Sarcoma Diagnosis and Treatment (37 papers), Cancer Treatment and Pharmacology (36 papers) and Colorectal Cancer Treatments and Studies (23 papers). Thomas Brodowicz is often cited by papers focused on Sarcoma Diagnosis and Treatment (37 papers), Cancer Treatment and Pharmacology (36 papers) and Colorectal Cancer Treatments and Studies (23 papers). Thomas Brodowicz collaborates with scholars based in Austria, Germany and France. Thomas Brodowicz's co-authors include Christoph Zielinski, Tudor–Eliade Ciuleanu, Chandra P. Belani, Maciej Krzakowski, Katherine P. Sugarman, Valentina Tzekova, Branka Čučević, Christoph Wiltschke, Patrick Peterson and William J. John and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Thomas Brodowicz

117 papers receiving 3.3k citations

Hit Papers

Maintenance pemetrexed plus best supportive care versus p... 2009 2026 2014 2020 2009 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    2009 832 citations Tudor–Eliade Ciuleanu, Thomas Brodowicz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Brodowicz Austria 28 2.4k 2.0k 585 468 417 126 3.4k
Roberto Petrioli Italy 28 1.6k 0.7× 1.2k 0.6× 508 0.9× 407 0.9× 855 2.1× 135 3.1k
Eva Lieto Italy 31 1.7k 0.7× 1.1k 0.6× 625 1.1× 443 0.9× 868 2.1× 67 3.1k
Nancy A. Dawson United States 33 1.3k 0.6× 2.6k 1.3× 945 1.6× 782 1.7× 369 0.9× 145 4.3k
Victoria Villaflor United States 28 1.5k 0.6× 1.2k 0.6× 600 1.0× 404 0.9× 742 1.8× 132 2.9k
Toshimi Takano Japan 25 2.1k 0.9× 1.7k 0.8× 628 1.1× 616 1.3× 246 0.6× 172 3.0k
Dominique Grunenwald France 28 1.3k 0.6× 2.1k 1.1× 299 0.5× 281 0.6× 755 1.8× 86 3.3k
Sun Min Lim South Korea 27 1.5k 0.6× 1.6k 0.8× 900 1.5× 521 1.1× 216 0.5× 132 2.8k
Yang Yao China 29 1.2k 0.5× 1.1k 0.5× 694 1.2× 302 0.6× 333 0.8× 125 2.4k
Conor Steuer United States 27 1.4k 0.6× 1.4k 0.7× 797 1.4× 512 1.1× 424 1.0× 121 2.8k
Matthew A. Gubens United States 30 3.4k 1.5× 2.3k 1.1× 565 1.0× 524 1.1× 288 0.7× 100 4.3k

Countries citing papers authored by Thomas Brodowicz

Since Specialization
Citations

This map shows the geographic impact of Thomas Brodowicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Brodowicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Brodowicz more than expected).

Fields of papers citing papers by Thomas Brodowicz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Brodowicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Brodowicz. The network helps show where Thomas Brodowicz may publish in the future.

Co-authorship network of co-authors of Thomas Brodowicz

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Brodowicz. A scholar is included among the top collaborators of Thomas Brodowicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Brodowicz. Thomas Brodowicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brodowicz, Thomas, Bernadette Liegl‐Atzwanger, Nicolas Penel, et al.. (2020). Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. Cancers. 12(12). 3746–3746. 8 indexed citations
2.
Kasper, Stefan, Diethelm Messinger, Regina Esser, et al.. (2020). Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. European Journal of Cancer. 144. 291–301. 7 indexed citations
3.
Brodowicz, Thomas, Olivier Mir, Jennifer Wallet, et al.. (2018). Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. European Journal of Cancer. 99. 28–36. 15 indexed citations
4.
5.
Brodowicz, Thomas, Peyman Hadji, Daniela Niepel, & Ingo Diel. (2017). Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer. Cancer Treatment Reviews. 61. 23–34. 26 indexed citations
6.
Touati, Nathan, Patrick Schöffski, Saskia Litière, et al.. (2017). EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: Clinical profile and response to systemic therapy. Annals of Oncology. 28. v528–v528. 1 indexed citations
7.
8.
Zielinski, Christoph, István Láng, S. Beslija, et al.. (2015). Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer. 114(2). 163–170. 21 indexed citations
9.
Brodowicz, Thomas, István Láng, Zsuzsanna Kahán, et al.. (2014). Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer. 111(11). 2051–2057. 24 indexed citations
10.
Bareck, Evelyne, Ahmed Ba‐Ssalamah, Thomas Brodowicz, et al.. (2013). Gastrointestinal stromal tumors: Diagnosis, therapy and follow-up care in Austria. Wiener Medizinische Wochenschrift. 163(5-6). 137–152. 10 indexed citations
11.
Schwameis, Katrin, Michael Schwameis, Reza Asari, et al.. (2013). Surgical treatment of GIST – An institutional experience of a high-volume center. International Journal of Surgery. 11(9). 801–806. 11 indexed citations
12.
Gnant, Michael, Marija Balić, Edgar Petru, et al.. (2012). Treatment of Bone Metastases in Patients with Advanced Breast Cancer. Breast Care. 7(2). 92–98. 11 indexed citations
13.
Brodowicz, Thomas, Tudor–Eliade Ciuleanu, Jeffrey Crawford, et al.. (2011). Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of Oncology. 23(5). 1223–1229. 23 indexed citations
14.
Köstler, Wolfgang J., et al.. (2010). Re: International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. JNCI Journal of the National Cancer Institute. 102(3). 207–207. 3 indexed citations
15.
Krainer, Michael, Gabriela Kornek, Gottfried J. Locker, et al.. (2005). Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience. Anti-Cancer Drugs. 16(2). 185–190. 3 indexed citations
16.
Jasińska, Joanna, Stephan N. Wagner, Christian Radauer, et al.. (2003). Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her‐2/neu. International Journal of Cancer. 107(6). 976–983. 45 indexed citations
17.
Brodowicz, Thomas, Daniela Kandioler, Christian Ludwig, et al.. (2001). Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status. British Journal of Cancer. 85(11). 1764–1770. 19 indexed citations
18.
Krainer, Michael, Thomas Brodowicz, Robert Zeillinger, et al.. (1997). Tissue Expression and Serum Levels of HER-2/neu in Patients with Breast Cancer. Oncology. 54(6). 475–481. 72 indexed citations
19.
Brodowicz, Thomas, Christoph Wiltschke, Alexandra C. Budinsky, et al.. (1997). Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cellsin vitro. International Journal of Cancer. 73(6). 875–879. 66 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberto Petrioli Breakdown of academic impact, for papers by Eva Lieto Breakdown of academic impact, for papers by Nancy A. Dawson Breakdown of academic impact, for papers by Victoria Villaflor Breakdown of academic impact, for papers by Toshimi Takano Breakdown of academic impact, for papers by Dominique Grunenwald Breakdown of academic impact, for papers by Sun Min Lim Breakdown of academic impact, for papers by Yang Yao Breakdown of academic impact, for papers by Conor Steuer Breakdown of academic impact, for papers by Matthew A. Gubens
Rankless by CCL
2026